Predictive value of peri-chemotherapy hematological parameters for febrile neutropenia in patients with cancer

• Published in: Frontiers in oncology Vol. 14; p. 1380195
• Main Authors: Jia, Hongyuan, Liang, Long, Chen, Xue, Zha, Wenzhong, Diao, Wei, Zhang, Wei
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 19.08.2024
• Subjects: chemotherapy; febrile neutropenia; hematological parameters; nomogram; Oncology; prediction; prediction; febrile neutropenia; nomogram; chemotherapy; hematological parameters
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2024.1380195

The aim of this study was to compare hematological parameters pre- and early post-chemotherapy, and evaluate their values for predicting febrile neutropenia (FN). Patients diagnosed with malignant solid tumors receiving chemotherapy were included. Blood cell counts peri-chemotherapy and clinical information were retrieved from the hospital information system. We used the least absolute shrinkage and selection operator (LASSO) method for variable selection and fitted selected variables to a logistic model. We assessed the performance of the prediction model by the area under the ROC curve. The study population consisted of 4,130 patients with common solid tumors receiving a three-week chemotherapy regimen in Sichuan Cancer Hospital from February 2019 to March 2022. In the FN group, change percentage of neutrophil count decreased less (-0.02, CI: -0.88 to 3.48 vs. 0.04, CI: -0.83 to 2.24). Among hematological parameters, lower post-chemotherapy lymphocyte count (OR 0.942, CI: 0.934-0.949), change percentage of platelet (OR 0.965, CI: 0.955-0.975) and higher change percentage of post-chemotherapy neutrophil count (OR 1.015, CI: 1.011-1.018), and pre-chemotherapy NLR (OR 1.002, CI: 1.002-1.002) predicted an increased risk of FN. These factors improved the predicting model based on clinical factors alone. The AUC of the combination model was 0.8275. Peri-chemotherapy hematological markers improve the prediction of FN.